Passa al contenuto
Merck

Vai a

G2295

Glimepiride

≥98% (HPLC), insulin secretagogue, solid

Autenticati per visualizzare i prezzi organizzativi e contrattuali.

Scegli un formato

Cambia visualizzazione
A voi/SKUDisponibilitàPrezzo
50 mg
Per conoscere la disponibilità, visualizza il carrello
CHF 177.00
250 mg
Per conoscere la disponibilità, visualizza il carrello
CHF 696.00
CHF 591.60

Informazioni su questo articolo

Formula empirica (notazione di Hill):
C24H34N4O5S
Numero CAS:
Peso molecolare:
490.62
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
Assay:
≥98% (HPLC)
Form:
solid

CHF 177.00


Per conoscere la disponibilità, visualizza il carrello

Richiedi un ordine in blocco
Servizio Tecnico
Hai bisogno di aiuto? Il nostro team di scienziati qualificati è a tua disposizione.
Permettici di aiutarti


Nome del prodotto

Glimepiride, ≥98% (HPLC), solid

Quality Segment

assay

≥98% (HPLC)

form

solid

color

white

mp

212.2-214.5 °C

solubility

DMSO: >10 mg/mL

originator

Sanofi Aventis

storage temp.

room temp

SMILES string

CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3)C1=O

InChI

1S/C24H34N4O5S/c1-4-21-17(3)15-28(22(21)29)24(31)25-14-13-18-7-11-20(12-8-18)34(32,33)27-23(30)26-19-9-5-16(2)6-10-19/h7-8,11-12,16,19H,4-6,9-10,13-15H2,1-3H3,(H,25,31)(H2,26,27,30)/t16-,19-

InChI key

WIGIZIANZCJQQY-RUCARUNLSA-N

Gene Information

General description

Glimepiride is a class II biopharmaceutical[1] second-generation sulfonylurea.

Application

Glimepiride has been used:
  • as a hypoglycemic drug to test its anti-diabetic functionality in human umbilical vein cells (HUVECs)[2]
  • as a sulfonylurea ATP-sensitive potassium channel (KATP) channel inhibitor in breast cancer MDA-MB-231 cells[3]
  • in glucose-stimulated insulin secretion (GSIS) assays of neonatal islet-like cell clusters (NICCs) to test its effect on insulin secretion[4]

Glimepiride is currently used to treat type 2 diabetes.

Biochem/physiol Actions

Glimepiride is a potent blocker of cardiac KATP channels activated by pinacidil with an IC50 of 6.8 nM.
Glimepiride reduces blood glucose levels by stimulating the pancreatic β cells to secrete insulin hormone. It interacts with a 65-kD protein associated with β cells.[1]
Potent blocker of cardiac KATP channels.

Features and Benefits

This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Confronta articoli simili

Visualizza il confronto per intero

Mostra le differenze

1 of 1

Questo articolo
BP1144Y0000515Y0000516
Glimepiride ≥98% (HPLC), solid

Sigma-Aldrich

G2295

Glimepiride

Glimepiride British Pharmacopoeia (BP) Reference Standard

BP1144

Glimepiride

Glimepiride European Pharmacopoeia (EP) Reference Standard

Y0000515

Glimepiride

assay

≥98% (HPLC)

assay

-

assay

-

assay

-

form

solid

form

solid

form

-

form

-

Quality Level

100

Quality Level

-

Quality Level

-

Quality Level

-

storage temp.

room temp

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

2-8°C

solubility

DMSO: >10 mg/mL

solubility

-

solubility

-

solubility

-

color

white

color

-

color

-

color

-


Still not finding the right product?

Explore all of our products under Glimepiride


pictograms

Health hazard

signalword

Warning

hcodes

Hazard Classifications

Repr. 2

Classe di stoccaggio

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)



Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documenti section.

Se ti serve aiuto, non esitare a contattarci Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti



Questions

Reviews

No rating value

Active Filters